| | | | | | |

International Team Identifies Potential New Mesothelioma Biomarker

ByAlex Strauss

22192140_Biomarker4A team of international researchers say they have identified a promising new biomarker for malignant pleural mesothelioma, a rare but deadly cancer caused by exposure to asbestos.

A biomarker is a compound found in the tissue, blood or other body fluid that is produced in higher amounts when disease is present.

In the case of a new report presented at the annual International Association for the Study of Lung Cancer conference, the potential mesothelioma biomarker is a protein called fibroblast growth factor 18 (FGF18).

Biomarkers for Mesothelioma Diagnosis and Prognosis

The identification of potential new diagnostic and prognostic biomarkers is especially important for people with pleural mesothelioma because there is no definitive test for the disease.

Often, diagnosing mesothelioma is a process of elimination involving tests and exams as well as a careful patient history including the likelihood that the suspected mesothelioma patient was exposed to asbestos, the primary cause of mesothelioma.

Biomarkers can not only help doctors determine whether a person may have malignant mesothelioma, but can also help them distinguish it from other lung-related conditions.

Biomarkers can also be useful in treatment planning by indicating which patients are likely to respond to which kinds of mesothelioma therapies. After a mesothelioma treatment is implemented, biomarkers can be used to help monitor the success of the therapy.

A New Mesothelioma Biomarker?

FGF18, the novel mesothelioma biomarker identified in the new report, is a member of the fibroblast growth factor family. It is involved in a number of biological processes, including tissue repair, cell growth, and tumor growth and invasion.

To test its potential as a mesothelioma biomarker, researchers collected plasma samples from 107 malignant pleural mesothelioma patients at hospitals in Vienna, Zagreb, and Sydney, Australia. Plasma samples were collected either when patients were diagnosed or right before they were scheduled for mesothelioma surgery.

The study also included 49 healthy people and 8 patients with non-malignant pleural diseases to serve as controls.

Analyzing the Results

The study found that FGF18 levels were “significantly elevated” in people with mesothelioma when compared to the healthy patients. People with the sarcomatoid mesothelioma subtype had the highest FGF18 levels. The results suggest that FGF18 could also be useful in determining mesothelioma prognosis.

“Importantly, malignant pleural mesothelioma patients presenting with FGF18 levels below the median had a significantly longer overall survival when compared to those with high FGF18 levels,” states the report.

Mesothelioma patients with FGF18 levels below the median survived for a median of 625 days versus just 382 days in those with the highest FGF18 levels. The report concludes that FGF18 is “a promising blood-derived candidate biomarker in malignant pleural mesothelioma” and may be useful not only as a diagnostic tool but also to determine patient prognosis.

Source:

Dong, Y, et al, “Circulating Fibroblast Growth Factor 18 is Elected in Malignant Pleural Mesothelioma Patients – A Multi-Institutional Study”, Paper presented at the International Association for the Study of Lung Cancer annual conference, December 2016, Vienna, Austria

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    ByAlex Strauss

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…